Clinical trials: New Onset Type-1 Diabetes
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Covid19, type1diabetes
Covid-19 Infection and New Onset Type 1 Diabetes
Although recognized as an autoimmune disease the etiology of type 1 diabetes remains unknown. Virus infections has been suggested as a possible agent triggering the autoimmune reaction finally resulting in beta-cell destruction…
- Trial name
- NCT04623697
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Type 1 Diabetes
Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes
This study is a multicenter, randomized, double-masked, placebo-controlled clinical study. All groups will receive standard intensive diabetes treatment with insulin and life style management.
- Trial name
- NCT01781884
- Testing
- Gamma Aminobutyric Acid (GABA)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Type 1 Diabetes, Insulin Dependent Diabetes
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
The primary objective of this study is to evaluate the action of DPP-IV inhibitors in the prevention of progressive beta cell dysfunction in patients with type 1 diabetes mellitus newly diagnosis ( less than 6 months).
- Conditions
- Type 1 Diabetes, Insulin Dependent Diabetes, Juvenile Onset Diabetes Mellitus, Autoimmune Diabetes
- Trial name
- NCT01559025
- Testing
- Vildagliptin
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- Federal University of São Paulo
New-onset Type 1 Diabetes
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
The objective of this clinical trial was to assess whether ladarixin treatment is effective to improve glycemic control in newly diagnosed Type 1 Diabetes (T1D) adult patients with preserved β-cell function.
- Trial name
- NCT04899271
- Testing
- Ladarixin
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes
Etanercept in New Onset Type 1 Diabetes
The investigators hypothesized that the administration of Etanercept to children newly diagnosed with T1DM may be able to interdict the progression of T1DM.
- Trial name
- NCT00730392
- Testing
- Etanercept
- Volunteers
- 18 people
- Sponsor
- State University of New York at Buffalo
Treatment of Type I Diabetes Mellitus.
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients.
- Trial name
- NCT01947569
- Testing
- Biological
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- DiaVacs, Inc.
Type 1 Diabetes Mellitus
Low Dose Cyclosporin and Methotrexate Therapy in Diabetes
The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus
- Trial name
- NCT00905073
- Testing
- cyclosporin and methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Diabetes Mellitus, Type 1
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicentre study of 52 weeks treatment duration.
- Trial name
- NCT02284009
- Testing
- Albiglutide weekly injection, Insulin
- Where
- 32 sites in France, Germany and 3 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Diabetes Mellitus, Type I
Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)
The objective of this study is to evaluate glycemic control of users of the AHCL system MiniMed 780G with GS4 calibration-free sensor in children and adolescents with newly diagnosed T1D implemented directly upon T1D diagnosis in…
- Trial name
- NCT06919029
- Testing
- Advanced Hybrid Closed Loop from onset of type 1 diabetes in children
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- National and Kapodistrian University of Athens
Diabetes Mellitus, Type 1 Diabetes
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
- Trial name
- NCT05866536
- Testing
- Bacillus Calmette-Guérin, Saline Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.
- Trial name
- NCT06227221
- Testing
- Sorafenib
- Volunteers
- 10 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 1, Hypoglycemia
Diabetes Islet Preservation Immune Treatment
To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
- Trial name
- DIPIT (NCT02586831)
- Testing
- Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide
- Sponsor
- Camillo Ricordi and Jay Skyler
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the…
- Conditions
- Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
- Trial name
- EXTEND (NCT02293837)
- Testing
- Tocilizumab (TCZ), Standard of Care
- Where
- 19 sites in United States, Australia
- Volunteers
- 136 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Time Limited Eating in Type 1 Diabetes
This study is a randomized-control pilot study that aims to evaluate Time Limited Eating (TLE) in the pediatric T1D population, implemented within the first six months after diagnosis.
- Trial name
- TLET1D (NCT05031429)
- Testing
- Time Limited Eating
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Los Angeles
Type 1 Diabetes
Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease and results from T cell autoimmunity mediated destruction of the majority of insulin-producing pancreatic β-cells.
- Trial name
- NCT01341899
- Testing
- immunosuppression and stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes
The purpose of this study is to address the safety issue of whether, in patients with newly-diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making…
- Trial name
- MonoPepT1De (NCT01536431)
- Testing
- Pro insulin peptide, Saline
- Where
- 5 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Cardiff University